About Sarepta Therapeutics
Sarepta Therapeutics is a company based in Cambridge (United States) founded in 1980. It operates as a HealthTech. The company has 1,370 employees. Sarepta Therapeutics has completed 1 acquisition, including Myonexus Therapeutics. Sarepta Therapeutics offers products and services including Gene Therapy Treatments, RNA Platform Solutions, and Gene Editing Therapies. Sarepta Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 1,370
- Stage Public
- SectorsHealthcare
- Website category Arts and Entertainment · Music
- Phone•••• ••••
- Website sarepta.com
- Social LinkedIn X Facebook Instagram
- Legal Name Sarepta Therapeutics, Inc.
- Annual Revenue$2.2 B (USD)15.58as on Dec 31, 2025
- Net Profit-$713.41 M (USD)-403.27as on Dec 31, 2025
- EBITDA-$599.3 M (USD)-320.35as on Dec 31, 2025
- Latest Funding Round$400M (USD), Post-IPO
Feb 2020
- InvestorsMorgan Stanley
& 8 more
- Employee Count1,370
- Investments & Acquisitions
Products & Services of Sarepta Therapeutics
Sarepta Therapeutics offers a comprehensive portfolio of products and services, including Gene Therapy Treatments, RNA Platform Solutions, and Gene Editing Therapies.
Gene therapies are developed for rare genetic diseases.
RNA technologies are utilized for rare disease treatments.
Gene editing is applied to address rare diseases.
Apps and channels of Sarepta Therapeutics
Sarepta Therapeutics publishes 1 mobile app with over 10 downloads.
Funding Insights of Sarepta Therapeutics
- Total Rounds 8
- Last Round Post-IPO — $400M
- First Round $1.35M
(Dec 2006)
- Investors Count 9
All 8 funding rounds of Sarepta Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2020 | $400M | Post-IPO | – | – | – |
| Nov 2019 | $30.5M | Post-IPO | – | – | – |
| Oct 2015 | $126.8M | Post-IPO | – | – | |
| Jun 2015 | $40M | Debt – Conventional | – | – | – |
| Nov 2010 | $1.2M | Grant | – | – | – |
| Feb 2010 | $500,000 | Grant | – | – | |
| Aug 2008 | $1.35M | Grant | – | – | |
| Dec 2006 | $1.35M | Grant | – | – |
9 investors in total: 9 institutional.
Investors in Sarepta Therapeutics
Sarepta Therapeutics has secured backing from 9 investors, including institutional investors. Prominent investors backing the company include Morgan Stanley, Credit Suisse and Baird.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Wealth management, investment advisory, and financial services are provided. | 1935 | morganstanley.com | New York, United States | |
Financial services including wealth management and investment banking are offered by Baird. | 1919 | rwbaird.com | Milwaukee, United States | |
Investment banking firm | 1985 | needhamco.com | New York, United States | |
Financial services are provided by William Blair to global clients. | – | williamblair.com | Chicago, United States | |
Mid-market investment bank | 1984 | roth.com | Newport Beach, United States | |
Wealth management, asset management, and investment banking services are offered. | 1856 | credit-suisse.com | Zurich, Switzerland | |
Nonprofit organization funding research and providing support for Duchenne patients. | 2009 | cureduchenne.org | Newport Beach, United States | |
Support is provided for research into Duchenne Muscular Dystrophy. | 2002 | duchennemd.org | Alexandria, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Sarepta Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sarepta Therapeutics
350 people are tracked at Sarepta Therapeutics (213 in leadership, 15 in board & advisors, 122 in team); the tracked headcount is 1,370.
| Name | Role | Group |
|---|---|---|
Mary Ann Gray | Member Board Of Directors | Leadership |
Pete Burke | Senior Director, Commercial RNA DS Manufacturing | Leadership |
Diane Berry | EVP & Chief Global Policy & Advocacy Officer | Leadership |
Betsy Mauter | Director, Research Operations - Compliance | Leadership |
Kinjal Amin | Director, Quality Control | Leadership |
John Haberman | Vice President, Chief Intellectual Property Officer | Leadership |
Ian M. Estepan | EVP & CFO | Leadership |
Rob Hesse | Director, Corporate Strategy | Leadership |
Sandra Rivas Msc | Senior Director Regulatory Affairs, Gene Therapy, Rare Disease | Leadership |
Deb Oriez | Director TMF Operations & Inspection Readiness | Leadership |
Damien D'Antonio | Senior Director, Gene Therapy Marketing | Leadership |
Adam Bussell | Senior Director | Leadership |
Nasir Khan | Executive Director, Head Of Technical Operations Strategy And Business Operations | Leadership |
Keila Elliot | Associate Director, Global HR Operations & HR Systems | Leadership |
Vincent Guerlavais | Senior Director, Discovery Chemistry | Leadership |
Dhaval Shah | Associate Director- Gene Therapy DP Msat/manufacturing | Leadership |
Bill Thornton | Chief Information Officer | Leadership |
Britt Kostraba | Associate Director Of Commercial Drug Product Operations | Leadership |
Sarah Jablonski Schandle | Associate Director, Global Scientific Communications | Leadership |
Jane Bendfeldt | Senior Director, External Reporting And Compliance | Leadership |
330 more people are available in the full profile.
Complete people profiles for Sarepta Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sarepta Therapeutics
Sarepta Therapeutics is a publicly listed company on the NASDAQ with ticker symbol SRPT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Jun 1997
- Listed onNASDAQ: SRPT
- Listed entitySarepta Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS8036071004
- Share price$17.85 (-1.98% on the day) · 2026-10-09
- Market capitalisation$1.89B
- EPS (diluted, trailing year)$-2.90
- Volume (last session)3,015,056
Financials of Sarepta Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.20B | -$713.4M | -$599.3M |
| 2024 | $1.90B | $235.2M | $272.0M |
| 2023 | $1.24B | -$536.0M | -$208.9M |
| 2022 | $933.0M | -$703.5M | -$475.6M |
| 2021 | $701.9M | -$418.8M | -$399.9M |
Detailed financial statements for Sarepta Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sarepta Therapeutics
Sarepta Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Myonexus Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Clinical stage gene therapy company developing treatments for Limb-girdle muscular dystrophy (LGMD) | myonexustx.com | Columbus, United States | 2017 | May 2018 | $165M |
Complete acquisition details for Sarepta Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sarepta Therapeutics
5 dated milestones of Sarepta Therapeutics across 40 years, from founding to its latest funding, stage changes and deals.
- Founded Sarepta Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.3M.
- Acquisition Acquires Myonexus Therapeutics.
- Funding Latest funding round, Post-IPO, of $400.0M.
Competitors of Sarepta Therapeutics
Sarepta Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. |
Detailed competitors of Sarepta Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sarepta Therapeutics
The website of Sarepta Therapeutics (sarepta.com) receives about 58.5K visits a month and ranks #703,049 among all websites worldwide, #8,929 in Music.
- Monthly visits58.5K
▲ 22.2% vs previous month
- Unique visitors20K
per month
- Global rank#703,049
among all websites
- Category rank#8,929
Arts and Entertainment · Music
- Bounce rate43%
- Pages per visit1.8
- Average visit26 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Sarepta Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
wtop.com | wtop.com | 100% | – | #10,790 | – |
| youtube.com | 72% | 30.4B | #2 | View details | |
localsyr.com | localsyr.com | 50% | – | #44,423 | – |
wtrf.com | wtrf.com | 50% | – | #65,358 | – |
wate.com | wate.com | 50% | – | #45,860 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Sarepta Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Sarepta Therapeutics
Complete news archive for Sarepta Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Sarepta Therapeutics
10 companies that operate in the same segment as Sarepta Therapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Sarepta Therapeutics
Sarepta Therapeutics was founded in 1980 and raised its 1st funding round 26 years after it was founded.
Sarepta Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Sarepta Therapeutics has 1,370 employees.
Annual revenue of Sarepta Therapeutics is $2.2B as on Dec 31, 2025.
Sarepta Therapeutics is engaged in the development of precision genetic medicines aimed at treating rare diseases. The company specializes in gene therapy, RNA technologies, and gene editing platforms. Focus areas include Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and Charcot-Marie-Tooth disease. Solutions are engineered to transform genetic understanding into effective treatments. Efforts are made to shorten drug development timelines and build significant gene therapy manufacturing capacity. Access and reimbursement models for innovative treatments are also rethought. The mission is centered on reclaiming futures impacted by rare diseases through relentless scientific advancement.
Sarepta Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Sarepta Therapeutics offers Gene Therapy Treatments, RNA Platform Solutions, and Gene Editing Therapies.
Yes, Sarepta Therapeutics is publicly traded on NASDAQ under the ticker symbol SRPT.
Sarepta Therapeutics has made 1 acquisition, including Myonexus Therapeutics.
Sarepta Therapeutics has 9 investors. Key investors include Morgan Stanley, Credit Suisse, Baird, HHS, and Needham.
Sarepta Therapeutics operates through Sarepta Therapeutics, Inc..
Yes. Sarepta Therapeutics publishes Exon Map Explorer, with over 10 downloads.